Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 + Adebrelimab + SHR-8068 +/- Carboplatin in Advanced NSCLC
NCT06434103Phase 2Withdrawn
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2024
- Primary completion
- Oct 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
01
Overview
A Phase 2 trial of tizetatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Oct 2024; status: withdrawn.
02
Drugs
tizetatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06434103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434103.